Skip to content

Denis Arikci

8 papers in the library · 161 citations · publishing 2023-2026

Papers

Sort Most recent Most cited

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.

Neuropsychopharmacology July 1, 2026 Denis Arikci, Joran Borgulya, Isabelle Straumann et al. 1 citation

Based on its in vitro profile and preliminary evidence, 4-bromo-2,5-dimethoxyphenethylamine (2C-B) may have psychoactive properties that are similar to 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin, which are investigated for the treatment of posttraumatic stress disorder and depressive disorders. We compared acute effects of 2C-B (10, 20, and 30 mg), 125 mg MDMA, and 25 mg psilocybin...

The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.

Journal of Psychopharmacology December 26, 2025 Kurt Stocker, Matthias Hartmann, Yasmin Schmid et al. 5 citations

The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-ASC offers superior model fit, the 3D-ASC...

Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study.

Clinical Pharmacology & Therapeutics May 26, 2025 Denis Arikci, Friederike Holze, Lorenz Mueller et al. 6 citations

Lysergic acid diethylamide (LSD) is currently being investigated as a potential treatment for psychiatric and neurological disorders. Different LSD formulations (base or tartrate, oral or intravenous) are being used. Unclear is whether LSD base and tartrate pharmacokinetics are equivalent. Additionally, LSD's absolute oral bioavailability is unknown. Therefore, we tested the bioequivalence of...

DOI: 10.1002/cpt.3726 (opens in new tab) Full text (opens in new tab) Psychedelics Pharmacology Drug absorption Medical research +1

Liquid chromatography-tandem mass spectrometry-based pharmacokinetic and metabolic analysis of 4-bromo-2,5-dimethoxyphenethylamine and its metabolites in human plasma.

Drug Metabolism and Disposition April 28, 2025 Jan Thomann, Deborah Rudin, Selina Kraus et al. 4 citations

4-Bromo-2,5-dimethoxyphenethylamine (2C-B) is widely used recreationally and has recently gained interest as a treatment for mental health disorders. In this study, a liquid chromatography-tandem mass spectrometry method to quantify 2C-B and its metabolites 4-bromo-2,5-dimethoxyphenylacetic acid (BDMPAA) and 4-bromo-2-hydroxy-5-methoxyphenylacetic acid (B-2-HMPAA) in human plasma was developed...

DOI: 10.1016/j.dmd.2025.100086 (opens in new tab) Full text (opens in new tab) Bioanalytical chemistry Bioanalysis Method validation Pharmacokinetics +4

Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.

Psychopharmacology March 26, 2025 Laura Ley, Matthias E. Liechti, Anna M Becker et al. 3 citations

Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospectively. This paper explored reasons why healthy people register for psychedelic trials, factors that they considered to contribute to either positive or negative study experiences, and under which circumstances they would seek a psychedelic experience...

The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research

Repository for Publications and Research Data 2025 Kurt Stocker, Matthias Hartmann, Yasmin Schmid et al.

Background: The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-ASC offers superior model fit, the...

DOI: 10.3929/ethz-c-000791180 (opens in new tab) Anxiety Revalidation Confirmatory factor analysis Rating scale +20

Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants.

Translational Psychiatry September 4, 2024 Patrick Vizeli, Erich Studerus, Friederike Holze et al. 15 citations

The pharmacodynamic effects of lysergic acid diethylamide (LSD) are diverse and different in different individuals. Effects of other psychoactive substances have been shown to be critically influenced by non-pharmacological factors such as personality traits and mood states. The aim of this study was to determine pharmacological and psychological predictors of the LSD effects in healthy human...

DOI: 10.1038/s41398-024-03074-9 (opens in new tab) Full text (opens in new tab) Personality psychology Psychopharmacology Mental states Psychedelics

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.

Neuropsychopharmacology October 1, 2023 Laura Ley, Friederike Holze, Denis Arikci et al. 127 citations

Mescaline, lysergic acid diethylamide (LSD), and psilocybin are classic serotonergic psychedelics. A valid, direct comparison of the effects of these substances is lacking. The main goal of the present study was to investigate potential pharmacological, physiological and phenomenological differences at psychoactive-equivalent doses of mescaline, LSD, and psilocybin. The present study used a...

DOI: 10.1038/s41386-023-01607-2 (opens in new tab) Full text (opens in new tab) Psychedelics Hallucinogens Comparative drug research Pharmacology